Tempest Therapeutics, Inc. filed a Form 8-K on November 6, 2026, disclosing that it received a Nasdaq deficiency notice on November 4, 2026, for failing to maintain the minimum $1.00 closing bid price requirement for its common stock.

Key Highlights

  • Deficiency notice received: Tempest Therapeutics received a letter from Nasdaq Listing Qualifications Staff on November 4, 2026.
  • Bid price below minimum: The company's common stock closed below $1.00 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
  • Initial compliance deadline: The company has 180 calendar days, until May 3, 2027, to regain compliance with the minimum bid price requirement.
  • Compliance threshold: To regain compliance, the closing bid price must reach at least $1.00 per share for a minimum of 10 consecutive business days before May 3, 2027.
  • No immediate listing impact: According to the filing, "the notification received has no immediate effect on the listing of the Company's common stock on the Nasdaq Stock Market or on the Company's business operations."
  • Potential second period: If the company does not comply by May 3, 2027, it may be eligible for an additional 180-day compliance period, subject to meeting certain conditions including providing written notice of intent to cure.

Nasdaq Minimum Bid Price Deficiency and Compliance Timeline for Tempest Therapeutics

According to the Form 8-K filed with the SEC, Tempest Therapeutics, Inc. (NASDAQ:TPST) disclosed that the Listing Qualifications Staff of The Nasdaq Stock Market LLC sent the company a formal notification on November 4, 2026. The notice stated that the company's common stock had closed below $1.00 per share for the last 30 consecutive business days, falling short of the continued listing requirement under Nasdaq Listing Rule 5550(a)(2).

The filing states that under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days from the date of the notice to regain compliance, setting a Compliance Date of May 3, 2027. Compliance would be achieved if the closing bid price meets or exceeds $1.00 per share for at least 10 consecutive business days before that deadline. The filing notes the notification has no immediate effect on the company's listing status or business operations.

The filing further discloses that if the company fails to regain compliance by May 3, 2027, it may qualify for a second 180-day compliance period, provided it meets the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards, excluding the bid price requirement, and submits written notice to Nasdaq of its intention to cure the deficiency, "by effecting a reverse stock split, if necessary." Should the company fail to qualify for or complete a second compliance period, Nasdaq would notify the company that its shares are subject to delisting, at which point the company could appeal to a Nasdaq hearings panel. The company stated it "intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and will evaluate available options to resolve the deficiency."

What Was Disclosed

Tempest Therapeutics disclosed receipt of a Nasdaq bid price deficiency notice dated November 4, 2026, triggering a 180-day compliance window ending May 3, 2027, with no immediate effect on its current Nasdaq listing or business operations.